The COVID-19 pandemic undeniably propelled messenger RNA (mRNA) vaccines into the global scientific and public consciousness, marking a pivotal moment in vaccinology. Following an unprecedented accelerated development and rigorous clinical trials, the world witnessed the administration of the first COVID-19 mRNA vaccine on December 8, 2020. The impact of this innovation was profound; researchers subsequently utilized sophisticated modeling techniques to estimate that these novel vaccines were responsible for preventing at least 14.4 million deaths worldwide during their inaugural year of deployment alone. This staggering figure underscores the revolutionary potential of mRNA technology in confronting infectious disease threats. The mRNA Revolution and Its Unforeseen Limitations The remarkable success of mRNA vaccines against SARS-CoV-2 ignited a fervent wave of scientific inquiry, redirecting significant research efforts toward developing similar vaccine platforms for a spectrum of other infectious diseases. Currently, numerous clinical trials are underway, exploring mRNA vaccine candidates targeting formidable pathogens such as the influenza virus, Respiratory Syncytial Virus (RSV), Human Immunodeficiency Virus (HIV), Zika virus, Epstein-Barr virus, and even tuberculosis bacteria. This broad application reflects the initial optimism surrounding the platform’s versatility and speed of development. However, alongside these advancements, ongoing studies of the COVID-19 mRNA vaccines have also brought to light important practical and immunological limitations, signaling a critical need for new, complementary vaccine strategies. These challenges span various aspects, from the variability of individual immune responses to the complexities inherent in large-scale production and distribution. One significant challenge identified is the variability in immune protection generated by COVID-19 mRNA vaccines. The level and duration of immune response can differ widely among individuals, and the protection afforded does not confer indefinite immunity. This issue is compounded by the relentless evolutionary pressure on SARS-CoV-2, which consistently produces new variants capable of partially evading existing immune defenses, including those induced by vaccination. Consequently, vaccines frequently require updating, necessitating a continuous cycle of research, development, and deployment that can be resource-intensive and logistically demanding. Beyond immunological nuances, practical hurdles associated with mRNA vaccine technology are also substantial. Manufacturing mRNA vaccines is a complex and expensive endeavor, involving intricate processes that are difficult to scale efficiently. A particular technical challenge lies in precisely controlling the number of mRNA molecules packaged into lipid nanoparticles (LNPs), which are crucial for delivering the genetic material into cells. Furthermore, mRNA vaccines are notorious for their stringent cold chain requirements, typically demanding ultra-low temperatures (e.g., -70°C for Pfizer-BioNTech or -20°C for Moderna) for storage and transportation. This necessity complicates distribution, especially in remote or under-resourced regions where specialized freezers and reliable cold chain infrastructure are scarce. The potential for unintended off-target effects, though generally rare, also remains a consideration. Addressing these multifarious limitations is paramount to bolstering global preparedness and enhancing the effectiveness of future responses to infectious disease pandemics. Introducing DoriVac: A DNA Origami Nanotechnology Platform In response to these pressing challenges, a pioneering multidisciplinary team—comprising researchers from the Wyss Institute at Harvard University, Dana-Farber Cancer Institute (DFCI), and their partner institutions—has ventured into an entirely different realm of vaccine development. They have explored and validated a novel approach utilizing a DNA origami nanotechnology platform dubbed DoriVac. This innovative platform distinguishes itself by functioning simultaneously as both a vaccine antigen presentation system and an immune-stimulating adjuvant, offering a dual-action mechanism designed for enhanced efficacy and stability. The foundational principle of DoriVac lies in DNA origami, a groundbreaking technique that employs the self-assembling properties of DNA strands to create intricate, custom-designed nanoscale structures. This allows for an unprecedented level of control over the vaccine’s molecular architecture. The researchers meticulously designed DoriVac vaccines to specifically target a conserved peptide region known as HR2, which is found within the spike proteins of several formidable viruses, including SARS-CoV-2, HIV, and Ebola. Targeting such conserved regions is a strategic move, aiming to elicit broader and potentially more durable immune responses that are less susceptible to viral mutations. Early preclinical studies conducted in mice yielded highly encouraging results. The SARS-CoV-2 HR2 DoriVac vaccine successfully triggered robust immune responses, encompassing both antibody-driven (humoral) activity and T cell-driven (cellular) immunity. To further validate these findings and bridge the translational gap between animal models and human physiology, the team ingeniously tested the vaccine in a preclinical human model. This involved utilizing the Wyss Institute’s cutting-edge microfluidic human Organ Chip technology, which precisely simulates a human lymph node in vitro. Within this sophisticated system, the SARS-CoV-2 HR2 DoriVac vaccine also generated potent antigen-specific immune responses in human cells, lending significant credence to its potential for human application. A direct comparison was then conducted between a DoriVac vaccine carrying the same spike protein variant and conventional SARS-CoV-2 mRNA vaccines delivered via lipid nanoparticles. The results, published in the esteemed journal Nature Biomedical Engineering, indicated that the DoriVac vaccine produced a similarly strong immune activation in human models. Crucially, however, the DNA origami vaccine demonstrated significant advantages in terms of stability, proving easier to store and manufacture. These attributes directly address some of the most critical logistical and practical limitations associated with current mRNA vaccine platforms. Dr. William Shih, a co-corresponding author, Wyss Institute Core Faculty member, and Professor at Harvard Medical School and DFCI, whose group pioneered the novel vaccine concept, articulated the platform’s promise. "With the DoriVac platform, we have developed an extremely flexible chassis with a number of critical advantages, including an unprecedented control over vaccine composition, and the ability to program immune recognition in targeted immune cells on a molecular level to achieve better responses," Shih stated. He emphasized, "Our study demonstrates DoriVac’s versatility and potential by taking a close look at the immune changes that are required to fight infectious viruses." The Architecture of DNA Origami Vaccines: Precision at the Nanoscale The genesis of DoriVac as a DNA nanotechnology-based vaccine platform with broad potential applications was first introduced in 2024 by Shih’s team at the Wyss Institute and Dana-Farber. Dr. Yang (Claire) Zeng, who spearheaded the foundational efforts with collaborators, demonstrated DoriVac’s extraordinary capability to precisely present immune-stimulating adjuvant molecules to cells at the nanoscale. This level of precision in molecular arrangement is believed to be key to eliciting potent and targeted immune responses. Earlier investigations, specifically in tumor-bearing mice, had already provided compelling evidence that DoriVac vaccines generated stronger immune responses compared to versions lacking the unique DNA origami structure. The construction of DoriVac vaccines involves tiny, self-assembling square DNA nanostructures. One face of these nanostructures is meticulously engineered to display adjuvant molecules, which are arranged at carefully controlled nanometer distances to optimize immune cell activation. The opposing face is designed to present selected antigens, which can be peptides or proteins derived from tumors or, in the case of infectious diseases, from pathogens. Dr. Zeng, who serves as a first and co-corresponding author on the new study and is now cofounder and CEO/CTO of DoriNano (a company leading the translation of this technology into clinical applications), recounted the platform’s pivot toward infectious diseases. "While we were developing the platform for cancer applications, the COVID-19 pandemic was still moving with full force. So, the question quickly arose whether DoriVac’s superior adjuvant activity could also be leveraged in infectious disease settings," she explained. To rigorously explore this intriguing hypothesis, Zeng and co-first author Dr. Olivia Young, a former graduate student in Shih’s group, initiated a collaborative effort with Dr. Donald Ingber’s team at the Wyss Institute. Ingber’s group is renowned for its antiviral innovation, employing advanced AI-driven and multiomics approaches in conjunction with sophisticated microfluidic human Organ Chip systems. Working in concert with co-first author Dr. Longlong Si, a former postdoctoral researcher in Ingber’s lab, the researchers successfully developed DoriVac vaccines designed to target SARS-CoV-2, HIV, and Ebola. These vaccines strategically present HR2 peptides, which function as critical, conserved antigens within the respective viral spike proteins. Zeng elaborated on the encouraging findings from the mouse studies: "Our analysis of the immune responses provoked by these first DoriVac vaccines in mice led to several encouraging observations, including significantly greater and broader activation of humoral and cellular immunity across a range of relevant immune cell types than what the origami-free antigens and adjuvants could produce." She further detailed the specific immune enhancements: "We found that the numbers of antibody-producing B cells, activated antigen-presenting dendritic cells (DCs), and antigen-specific memory and cytotoxic T cell types that are vital for long-term protection were all increased, especially in the case of the SARS-CoV-2 HR2." This comprehensive activation of both arms of the adaptive immune system is a hallmark of an effective vaccine. Bridging the Gap: From Mouse Models to Human Organ Chips A persistent and formidable challenge in vaccine development is the translational gap between preclinical studies in animal models and human clinical outcomes. Immune responses observed in mice, while informative, often do not fully recapitulate the complexities of the human immune system, leading to numerous promising treatments failing during later-stage clinical trials. To mitigate this risk and enhance the predictability of human outcomes, the research team strategically employed a human lymph node-on-a-chip (human LN Chip) to test the DoriVac vaccines. This advanced in vitro system, which mimics key aspects of the human immune system, represents a significant leap forward in preclinical evaluation. This cutting-edge system, further advanced by co-first author Min Wen Ku and co-corresponding author Dr. Girija Goyal, Director of Bioinspired Therapeutics at the Wyss Institute, provided crucial validation. The human LN Chip experiments demonstrated that the SARS-CoV-2-HR2 DoriVac vaccine effectively activated human dendritic cells (DCs) and significantly boosted their production of inflammatory cytokines, a critical step in initiating a robust immune response, when compared with origami-free components. Furthermore, the system revealed an increase in the number of CD4+ and CD8+ T cells, which are crucial for orchestrating and executing protective immune functions, lending further robust support to the platform’s potential for human therapeutic use. Dr. Donald Ingber, a co-corresponding author, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences, underscored the significance of this technology. "The predictive capabilities of human LN Chips gave us an ideal testing ground for DoriVac vaccines, and the induced, antigen-specific immune cell profiles and activities very likely reflect those that would occur in human recipients of the vaccines," Ingber stated. He concluded, "This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines and create a new testbed for future vaccine developments," highlighting the synergistic power of advanced bioengineering and immunology. DoriVac Versus mRNA: A Head-to-Head Comparison To firmly establish DoriVac’s competitive standing, the researchers undertook a direct comparative study against established mRNA vaccine technologies. Led by Zeng and co-author Qiancheng Xiong, the team evaluated a DoriVac vaccine presenting the full SARS-CoV-2 spike protein. This candidate was then compared directly with commercially available mRNA lipid nanoparticle (LNP) vaccines from Moderna and Pfizer/BioNTech, which encode the identical spike protein antigen. Using a standard booster vaccination approach in mice, the head-to-head comparison yielded compelling results: both vaccine types produced similar robust antiviral T cell and antibody-producing B cell responses. This finding is profoundly significant, as it demonstrates that DoriVac can achieve an equivalent level of immunological efficacy to the current gold standard mRNA vaccines, at least in preclinical models. Dr. Shih elaborated on the profound implications of these findings. "This underscored DoriVac’s potential as a DNA nanotechnology-enabled, self-adjuvanted vaccine platform," he affirmed. However, Shih emphasized that DoriVac possesses a multitude of other practical advantages that could redefine global vaccine accessibility and deployment. "DoriVac vaccines don’t have the same cold-chain requirements as mRNA-LNP vaccines do and thus could be distributed much more effectively, especially in under-resourced regions; and they could overcome some of the enormous manufacturing complexities of LNP-formulated vaccines, to name two major ones," he noted. The elimination of ultra-cold storage requirements represents a paradigm shift, enabling broader distribution and reducing logistical burdens in areas lacking sophisticated infrastructure. Furthermore, the inherent simplicity and cost-effectiveness of DNA origami assembly could significantly streamline manufacturing processes. Recent studies conducted at DoriNano have also provided encouraging evidence regarding DoriVac’s promising safety profile, further bolstering its potential for clinical translation. Broader Impact and Future Horizons The emergence of the DoriVac platform carries profound implications for global health security and future pandemic preparedness. Its inherent stability at ambient temperatures and simplified manufacturing process could dramatically enhance vaccine accessibility, particularly in low- and middle-income countries that struggle with the logistical and infrastructural demands of mRNA vaccines. This would foster greater vaccine equity, ensuring that effective preventative measures are not limited by economic or geographical constraints. Moreover, the modularity and precise control offered by DNA origami nanotechnology suggest a versatile platform adaptable to a wide array of infectious agents, and potentially even non-infectious diseases such as cancer or autoimmune disorders, building on DoriVac’s origins in cancer research. The ability to precisely arrange antigens and adjuvants at the nanoscale offers unprecedented opportunities to fine-tune immune responses, potentially leading to vaccines that are not only more potent but also more tailored to specific pathogens or patient populations. The successful validation in human organ-on-a-chip models represents a crucial step in accelerating the development pipeline, offering a more predictive preclinical testing ground that could reduce the attrition rate of promising vaccine candidates in later clinical trials. As the world continues to grapple with existing pathogens and brace for future outbreaks, platforms like DoriVac offer a beacon of hope for developing more resilient, accessible, and effective vaccine technologies. The next logical steps for DoriVac will involve further rigorous preclinical studies, followed by the preparation of an Investigational New Drug (IND) application to the appropriate regulatory bodies, paving the way for crucial Phase 1 human clinical trials. The extensive research behind DoriVac was made possible through significant collaborative efforts and funding from various prestigious institutions and programs. Key contributors to the study include Sylvie Bernier, Hawa Dembele, Giorgia Isinelli, Tal Gilboa, Zoe Swank, Su Hyun Seok, Anjali Rajwar, Amanda Jiang, Yunhao Zhai, LaTonya Williams, Caleb Hellman, Chris Wintersinger, Amanda Graveline, Andyna Vernet, Melinda Sanchez, Sarai Bardales, Georgia Tomaras, Ju Hee Ryu, and Ick Chan Kwon. Funding was generously provided by the Director’s Fund and Validation Project program of the Wyss Institute; the Claudia Adams Barr Program at DFCI; the National Institutes of Health (U54 grant CA244726-01); the US-Japan CRDF global fund (grant R-202105-67765); the National Research Foundation of Korea (grants MSIT, RS-2024-00463774, RS-2023-00275456); the Intramural Research Program of the Korea Institute of Science and Technology (KIST); and the Bill and Melinda Gates Foundation (INV-002274). This broad base of support underscores the scientific community’s recognition of DoriVac’s transformative potential in the evolving landscape of global public health. Post navigation Shingles Vaccine Offers Clearest Evidence Yet of Dementia Protection, Pioneering Welsh Study Reveals Significant 20% Risk Reduction.
